Your session is about to expire
← Back to Search
Mind Wandering Intervention for Attention Deficit Disorder
N/A
Waitlist Available
Led By Paul T. Cirino, PhD
Research Sponsored by University of Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
enrollment in schools where we have permission to conduct the study
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only.
Awards & highlights
Study Summary
This study assesses the impact of mind-wandering on reading and math.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~on 12 occasions interspersed during each of the math and reading learning sessions, on day 1 only.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Investigator Developed Items Derived From Math Content Being Taught
Investigator Developed Items Derived From Reading Content Being Taught
Secondary outcome measures
Investigator Developed Probe-Caught Mind-Wandering
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Mind Wandering InterventionExperimental Treatment1 Intervention
75% of participants will receive proactive and reactive mind-wandering information and redirection.
Group II: Mind Wandering ComparisonActive Control1 Intervention
25% of participants will receive only mind-wandering redirection, but only at random times.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mind-wandering intervention
2022
N/A
~60
Find a Location
Who is running the clinical trial?
University of HoustonLead Sponsor
146 Previous Clinical Trials
47,484 Total Patients Enrolled
Paul T. Cirino, PhDPrincipal InvestigatorUniversity of Houston
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger